Palivizumab Uses, Dosage, Side Effects and more

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Attribute	Details
Trade Name	Palivizumab
Availability	Prescription only
Generic	Palivizumab
Palivizumab Other Names	Palivizumab
Related Drugs	ribavirin, Synagis, respiratory syncytial virus immune globulin, RespiGam
Weight	100mg/ml,
Type	Intramuscular Solution, Intramuscular
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	January 7, 2025 at 1:49 am

Uses

Palivizumab is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.

For prophylaxis of respiratory diseases casued by respiratory syncytial virus.

Palivizumab is also used to associated treatment for these conditions: Infections, Respiratory Syncytial Virus